An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

January 28, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

EGF-R Positive Non-Small Cell Lung CancerCNS Metastases

Interventions

DRUG

Furmonertinib

Patients treated with Furmonertinib mesilate tablets orally

Trial Locations (1)

RECRUITING

Tangdu Hopspital, Xi’an

All Listed Sponsors

lead

Tang-Du Hospital

OTHER